These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Diagnostic challenges of clonal heterogeneity in prostate cancer. Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011 [No Abstract] [Full Text] [Related]
4. The management of localized prostate cancer. Clarke NW Br J Hosp Med; 1996 Mar 6-19; 55(5):232-3. PubMed ID: 8777510 [No Abstract] [Full Text] [Related]
5. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. Mystakidou K; Katsouda E; Parpa E; Vlahos L J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610 [TBL] [Abstract][Full Text] [Related]
6. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy? Schriefer P; Steurer S; Huland H; Graefen M J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622 [No Abstract] [Full Text] [Related]
7. [The role of PSA in prostatic adenocarcinoma]. Manca GP Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981 [TBL] [Abstract][Full Text] [Related]
8. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma]. Stamey TA Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883 [TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the prostate. Swanson JO J Insur Med; 1997; 29(3):195-203. PubMed ID: 10176369 [TBL] [Abstract][Full Text] [Related]
11. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion. Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840 [TBL] [Abstract][Full Text] [Related]
12. Adenocarcinoma of the prostate gland. Finkelstein LH J Am Osteopath Assoc; 1983 Apr; 82(8):543-6. PubMed ID: 6853232 [No Abstract] [Full Text] [Related]
13. Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels. Valle J; von Boguslawsky K; Stenborg M; Andersson LC Scand J Urol Nephrol; 1996 Dec; 30(6):509-12. PubMed ID: 9008037 [TBL] [Abstract][Full Text] [Related]
17. [A case of prostate cancer with invasion to the middle ureter]. Matsuo T; Hayashida Y; Takehara K; Tsuda S; Furukawa M; Iwasaki S Hinyokika Kiyo; 2004 Jan; 50(1):61-3. PubMed ID: 15032020 [TBL] [Abstract][Full Text] [Related]
18. Current status of cancers of the bladder and prostate. Jacobs SC; Campbell EW; Naslund MJ Trans Assoc Life Insur Med Dir Am; 1991; 74():144-51. PubMed ID: 1853521 [No Abstract] [Full Text] [Related]
19. Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site. Harper CL; Lofts FJ; Otter M; Mansi JL Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):367-8. PubMed ID: 8696637 [No Abstract] [Full Text] [Related]
20. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml. Stephan C; Jung K; Cammann H Cancer; 2004 May; 100(9):1989-90; author reply 1989-90. PubMed ID: 15112283 [No Abstract] [Full Text] [Related] [Next] [New Search]